Global Pulmonary Drug Delivery Systems Market Report to 2027

DUBLIN, January 3, 2023 /PRNewswire/ — “Pulmonary Drug Delivery Systems: Technologies and Global Markets” report has been added to offering.



This report will provide a detailed look at the Pulmonary Drug Delivery Systems market, highlighting the major lung diseases with detailed epidemiology for major disease areas such as asthma, COPD, and cystic fibrosis. The report includes an industry-wide assessment of new products, launches, recent approvals, R&D pipeline and blockbuster medicines.

The report discusses the regulatory landscape of pulmonary drug delivery systems for each device type. This will include products approved by regulators in recent years. Products under development or in various stages of clinical trials are also analysed.

The report includes profiles of key companies in the Pulmonary Drug Delivery Systems market, with overviews of their key product offerings and financials.

Companies mentioned

  • 3M

  • Laboratories Abbott

  • Astrazeneca

  • Boehringer Ingelheim GmbH

  • Cipla

  • Dr Reddy Ltd Laboratories

  • GlaxoSmithKline plc

  • Philips Respironics

  • Lupine

  • Mylan NV

  • Merck Kgaa

  • Novartis AG

  • Omron Corp.

  • Pfizer Inc.

  • Pulmatrix Inc.

  • Teva Pharmaceuticals Industries Ltd.

The report includes

  • 44 tables

  • A brief overview and up-to-date analysis of the global Pulmonary Drug Delivery Systems markets

  • Analysis of global market trends, with historical data on market revenues from 2019 to 2021, estimates for 2022 and projections of compound annual growth rates (CAGR) to 2027

  • Actual market size estimation and revenue forecast for Pulmonary Drug Delivery Systems by USD value and the corresponding market share analysis by drug delivery systems type, area of ​​application/disease and region

  • Highlights of major lung diseases with detailed epidemiology for major disease areas such as asthma, COPD, and cystic fibrosis; in addition, an industry-wide assessment of key developments, new products, recent approvals, R&D activities, pipeline products and blockbusters

  • In-depth information (facts and figures) on market drivers, opportunities and challenges, and other macroeconomic forces impacting the global Pulmonary Drug Delivery Systems market

  • Holistic review of the international regulatory landscape for pulmonary drug delivery systems with emphasis on newly approved products and products in development or in different stages of clinical trials

  • Up-to-date information on key M&A deals, deals, collaborations, and other impacting strategies adopted by key players in the global Pulmonary Drug Delivery Systems market

  • Evaluation of recently issued and granted patents on pulmonary drug delivery systems and related technologies

  • Identification of key stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues

Pulmonary administration of the drug is an alternative to oral administration of the drug. Pulmonary administration of the drug is mainly advantageous for the treatment of respiratory diseases because it involves systemic administration through the alveolar region, which leads to rapid absorption. The method of pulmonary drug delivery depends on the development of simple, inexpensive, and easy-to-use devices. These devices are designed to facilitate consistent drug delivery with increased lung penetration and multi-dose designs. Currently, manufacturers are focusing on developing small, portable devices that encourage greater patient compliance.

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide according to the World Health Organization (WHO). In low- and middle-income countries, deaths from COPD in individuals under the age of 70 account for nearly 90% of all deaths in low- and middle-income countries (LMICs).

To halt the progression of symptoms and reduce exacerbations, early diagnosis and treatment are needed, including smoking cessation support. Major risk factors for COPD include occupational exposure to dust, fumes, and chemicals; indoor air pollution; and tobacco smoke. Long-term exposure to toxic gases and particles combined with individual factors, such as events affecting childhood lung development and genetics, cause COPD. COPD causes persistent and progressive respiratory symptoms, such as coughing up phlegm and difficulty breathing.

The market for pulmonary drug delivery systems is growing rapidly due to the increasing prevalence of respiratory disorders such as asthma, COPD and other chronic diseases. Other factors driving its growth are the emergence of new inhaler designs and increased use of non-invasive drug delivery methods.

Main topics covered:

chapter 1 introduction

Chapter 2 Summary and Highlights

Chapter 3 Market dynamics and technological background
3.1 Market definition and overview
3.1.1 Mechanism of action
3.1.2 Benefits
3.1.3 Limitations/Challenges
3.2 Pulmonary conditions and therapies
3.2.1 Introduction to the respiratory system
3.3 Drivers and market trends
3.3.1 Increased patient compliance and ease of use
3.3.2 Cost pressures on countries
3.3.3 Increased incidence of asthma
3.3.4 Causes
3.3.5 Reduce the asthma burden
3.4 Market Restrictions
3.4.1 Competition from generics on the rise
3.5 Market Opportunity
3.5.1 Introduction to smart nebulizers
3.6 Regulation and legislation
3.6.1 USA

Chapter 4 Market Breakdown for Pulmonary Drug Delivery Systems
4.1 Overview of inhalation techniques
4.2 Dry Powder Inhalers (Dpi)
4.2.1 Overview
4.2.2 Marketed products
4.3 Metered-dose Inhalers (Mdis)
4.3.1 Overview
4.3.2 Marketed products
4.4 Nebulizers
4.4.1 Overview
4.4.2 Overview of marketed products by manufacturer

Chapter 5 Impact of Covid-19
5.1 Overview
5.2 Covid-19 crisis
5.3 Pulmonary Drug Delivery Systems Market Impact
5.4 Current Perspectives

Chapter 6 Pulmonary drug delivery systems in use
6.1 Therapeutic agents administered by inhalation
6.1.1 Steroids
6.1.2 Bronchodilators

Chapter 7 Market Breakdown by Disease Area

Chapter 8 Market Breakdown by Region

Chapter 9 Patent analysis

Chapter 10 Company Profiles

Chapter 11 Appendix: Abbreviations

For more information about this report, please visit

Media contact:
Research and Markets
Laura WoodChief director
[email protected]

For EST office hours call +1-917-300-0470
For US/CAN Call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716




View original content:—introduction-of-smart-nebulizers-presents-opportunities – 301712221.html

SOURCE Research and markets

Add a Comment

Your email address will not be published. Required fields are marked *